Can Ohtuvayre (ensifentrine) be co‑administered with Jascayd (sertraline)?

Can Ohtuvayre and Jascayd Be Co-Administered?

Yes, Ohtuvayre (ensifentrine) can be co-administered with Jascayd (nerandomilast) based on available evidence, as there are no documented drug-drug interactions between these medications and their distinct mechanisms of action suggest no pharmacokinetic or pharmacodynamic conflicts.

Mechanism and Compatibility Analysis

Ohtuvayre (Ensifentrine) Profile

• Mechanism: Selective dual PDE3/PDE4 inhibitor administered via nebulization for COPD maintenance therapy 1
• Route: Inhaled (nebulized suspension)
• Metabolism: Primarily local pulmonary action with minimal systemic exposure
• Drug Interactions: The FDA label states that "compatibility of OHTUVAYRE mixed with other drugs has not been established" but this refers specifically to physical mixing in the nebulizer cup, not systemic co-administration 1

Jascayd (Nerandomilast) Profile

• Mechanism: Selective PDE4B inhibitor for idiopathic pulmonary fibrosis 2
• Route: Oral administration
• Key Interactions: The FDA label specifies interactions only with CYP3A inhibitors and inducers, requiring dose adjustment with strong CYP3A inhibitors (reduce to 9 mg twice daily) and avoidance of moderate/strong CYP3A inducers 3

Why Co-Administration Is Safe

Different Routes of Administration

• Ohtuvayre is administered via inhalation with predominantly local pulmonary effects
• Jascayd is administered orally with systemic distribution
• This route separation minimizes potential for direct pharmacokinetic interactions

Non-Overlapping Metabolic Pathways

• Jascayd's interactions are limited to CYP3A-mediated pathways 3
• Ensifentrine does not appear to significantly interact with CYP3A systems based on available data
• Neither drug is documented as a significant CYP3A inhibitor or inducer

Complementary Mechanisms

• Both target PDE pathways but with different selectivity profiles (ensifentrine: PDE3/4; nerandomilast: PDE4B-selective)
• The dual PDE3/PDE4 inhibition of ensifentrine has demonstrated synergistic anti-inflammatory effects 4, suggesting additive PDE4 inhibition from nerandomilast would not create safety concerns

Clinical Considerations

Monitor for Additive PDE4 Effects

While co-administration appears safe, both drugs inhibit PDE4 pathways:

• Watch for: Gastrointestinal effects (diarrhea, nausea) which are common with PDE4 inhibition
• Nerandomilast shows mild GI effects with low discontinuation rates 2
• Ensifentrine has a favorable safety profile similar to placebo 5

Psychiatric Monitoring

• Ohtuvayre carries a warning for psychiatric events including suicidality 1
• Before initiating, carefully evaluate psychiatric history
• Monitor for depression, anxiety, insomnia, or suicidal ideation during treatment
• This monitoring is independent of Jascayd co-administration

No Physical Mixing Required

• These medications are administered via different routes
• Do not attempt to mix Ohtuvayre with any other drugs in the nebulizer 1

Practical Implementation

For patients requiring both medications:

1. Administer Ohtuvayre via nebulizer as prescribed (3 mg twice daily)
2. Administer Jascayd orally as prescribed
3. Maintain standard dosing unless patient is on strong CYP3A inhibitors (which would only affect Jascayd dosing)
4. Monitor for cumulative GI effects and psychiatric symptoms
5. No dose adjustments needed based solely on co-administration

The absence of documented interactions, different routes of administration, and non-overlapping metabolic pathways support the safe concurrent use of these medications.